NCT03907475 2026-04-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
Verastem, Inc.
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Gruppo Oncologico del Nord-Ovest
Phanes Therapeutics
Taiho Pharmaceutical Co., Ltd.